White-Collar Crime 7 Shocking Cases

Theranos is a useful case study because it wasn’t just one person’s lie — it exploited specific, structural features of how Silicon Valley funds and evaluates startups. Here’s how those dynamics played out:

1. “Stealth mode” as a legitimate excuse for secrecy

In tech culture, it’s normal and even expected for startups to operate in “stealth mode” — withholding details about their technology to protect IP from competitors before a big reveal. Theranos used this norm to justify refusing to let outside scientists or journalists examine the Edison device or validate its claims. In most industries, a company claiming to revolutionize medical diagnostics without peer-reviewed data would be laughed out of the room. In Silicon Valley’s culture, secrecy was treated as a sign of competitive advantage rather than a red flag.

2. Bypassing peer review and scientific norms

Theranos never published its methodology in peer-reviewed journals, which is close to unthinkable in legitimate biotech and medical device development. But Holmes marketed Theranos more like a tech company than a medical one — and tech culture doesn’t require peer review before shipping a product. Investors used to funding software startups applied the same “ship fast, iterate later” mental model to a company handling people’s blood and medical diagnoses, where that model is genuinely dangerous.

3. Investor FOMO and pattern-matching to charisma over substance

Holmes was young, charismatic, Stanford-affiliated (even though she dropped out), and telling a compelling mission-driven story: cheaper, less painful blood testing that could save lives. Venture capital famously runs on pattern recognition — investors look for founders who “feel like” the next Steve Jobs or Zuckerberg. Holmes deliberately cultivated this image (the black turtleneck, the deep affect she reportedly adopted for her voice), and it worked as a proxy for competence in a system that often prizes narrative and founder charisma over technical due diligence.

4. The board problem: prestige without expertise

Theranos’s board included figures like former Secretaries of State Henry Kissinger and George Shultz, former Senator Sam Nunn, and retired military generals. This gave enormous credibility by association — if someone of Kissinger’s stature was involved, surely the technology was real. But almost none of them had scientific, medical, or biotech backgrounds capable of evaluating whether the Edison device actually worked. This is a distinct failure mode from Theranos’s investors: it wasn’t that the board was negligent about finances (like Enron’s), it’s that the board was fundamentally unqualified to assess the core claim of the business, and nobody structured it to include people who could.

5. Avoiding traditional biotech investors

Notably, most experienced healthcare and biotech venture capital firms declined to invest in Theranos — many later said their technical due diligence raised concerns Holmes couldn’t or wouldn’t answer. Instead, Theranos raised money largely from generalist investors, wealthy individuals, and family offices (including Rupert Murdoch, the Walton family, and the DeVos family) who lacked the specialized expertise to scrutinize a diagnostics claim. This is a critical structural point: the fraud partly succeeded because it avoided the investors most likely to catch it.

6. Non-disclosure culture protecting the fraud internally

Silicon Valley’s aggressive NDA and non-compete culture, normally used to protect legitimate trade secrets, was weaponized at Theranos to silence internal dissent. Employees who raised concerns about test accuracy faced threats of expensive litigation and surveillance. Whistleblower Tyler Shultz (grandson of board member George Shultz) described being followed and threatened with lawsuits by Theranos’s lawyers, a level of legal aggression toward internal critics.

7. Regulatory gaps for lab-developed tests

Theranos exploited a genuine regulatory loophole: tests developed and run entirely within a single lab (called laboratory-developed tests, or LDTs) faced far less FDA scrutiny than a medical device sold to other labs or hospitals. This let Theranos operate largely outside rigorous premarket review for years, since it was technically running “its own lab” rather than selling a certified device to others.

The bigger pattern this reveals in White-collar crime

Theranos shows what happens when a “move fast, disrupt everything” funding culture — appropriate for software, where failure just means a buggy app — gets applied uncritically to a field like medicine, where failure can hurt or kill people. Uber, Airbnb, and many successful tech companies also famously operated in regulatory gray areas and outran scrutiny in their early years; the difference is a broken app doesn’t return a false cancer screening result. Silicon Valley’s tolerance for regulatory arbitrage and unverified claims, which is often rewarded in software, became actively dangerous once ported into a life-sciences context.

…

Next up: what role does law enforcement play in tackling white-collar crime?